Answers are grounded in this paper and cite their sources.
Clinical study demonstrates high initial response but notable bleeding risk with image-guided brachytherapy in frail rectal cancer, highlighting the need for careful patient selection.
Purpose For elderly and frail patients with rectal cancer, unfit for radical surgery or extensive chemoradiation schedules, radiotherapy dose escalation by use of high-dose-rate brachytherapy (HDR-BT) may be an alternative organ-preserving approach. Methods 15 elderly/frail patients (median age, 83 years; ECOG 1‑2: 80%) with histologically confirmed rectal adenocarcinoma (T1–3, N0–1, M0; UICC stage I-IIIB) were treated with definitive radiotherapy consisting of external beam radiation therapy (EBRT) of 30–39 Gy in 10–13 fractions, followed by image-guided endorectal HDR-BT with 12–24 Gy in 2–3 fractions. Acute and late toxicity of combined EBRT and HDR-BT was recorded according to CTCAE v5.0. Initial tumor response (clinical complete response, cCR, near clinical complete response, ncCR, and incomplete response, IR) and long-term disease control were assessed using clinical examination, endoscopy, and magnetic resonance imaging. Results Median follow-up was 21 (range, 9–43) months. Six weeks after completion of EBRT + HDR-BT, cCR ( n = 6) or ncCR ( n = 6) was confirmed in 12/15 patients (80%), 3 patients (20%) had IR. Local regrowth after initial ( n )cCR was observed in 4 patients (33%). A total of 4/15 patients (27%) developed distant metastases (2 with IR, 2 with ( n )cCR). Most common acute toxicities were mild/moderate proctitis (grade 1–2) in 67%, and mild grade 2 cystitis in 27%. Three patients (20%), of whom two were receiving oral anticoagulation, experienced late grade 3 rectal bleeding, requiring blood transfusion. One patient developed grade 3 rectal ulcer with necrosis treated with rectal amputation. Conclusions HDR-BT dose escalation after initial EBRT represents a feasible non-operative treatment option for patients unfit for surgery with promising long-term local control. The incidence of late grade 3 rectal bleeding, especially in patients receiving concomitant oral anticoagulation, requires careful patient selection, and further dose and treatment optimization (as implemented in the upcoming ACO/ARO/AIO-22 trial).
No takes yet. Share an insight, caveat, or question.
Kristen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: